Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1994;84:794-797
© 1994 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RODRIGUEZ, G. C.
Right arrow Articles by HAMMOND, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RODRIGUEZ, G. C.
Right arrow Articles by HAMMOND, C. B.

Serum Progesterone for the Exclusion of Early Pregnancy in Women at Risk for Recurrent Gestational Trophoblastic Neoplasia

GUSTAVO C. RODRIGUEZ, MD, CLAUDE L. HUGHES, MD, JOHN T. SOPER, MD, ANDREW BERCHUCK, MD, DANIEL L. CLARKE-PEARSON, MD and CHARLES B. HAMMOND, MD

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina

Abstract

Objective: To evaluate the utility of the serum progesterone level for discriminating pregnancy from gestational trophoblastic neoplasia.

Methods: Serum progesterone levels were measured in 61 women with histories of trophoblastic disease who developed a re-elevation in hCG during surveillance and underwent a work-up to differentiate pregnancy from gestational trophoblastic neoplasia. Progesterone levels were analyzed in the context of diagnostic outcome (pregnancy versus gestational trophoblastic neoplasia) to identify optimal threshold levels of progesterone to be used for classifying outcome.

Results: Of the 61 women, 37 proved to be pregnant and 24 had gestational trophoblastic neoplasia. Progesterone less than 2.5 ng/mL was predictive of trophoblastic malignancy, with a sensitivity of 83% (20 of 24 subjects were classified correctly as having gestational trophoblastic neoplasia) and a specificity of 95% (35 of 37 patients with progesterone levels at or above 2.5 ng/mL were correctly classified as pregnant). Progesterone of at least 10 ng/mL was associated with viable pregnancy in 97% of the cases. Furthermore, the progesterone level predicted outcome regardless of the serum hCG value.

Conclusion: The serum progesterone level is useful for discriminating early pregnancy from gestational trophoblastic neoplasia.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American College of Obstetricians and Gynecologists.